Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: A retrospective case series of 30 patients

Pharmacotherapy

Volumn 29, Issue 7, 2009, Pages 792-799

  Gallagher, Jason C ^a   Perez, Mirza E ^a   Marino, Elizabeth A ^a   LoCastro, Laura G ^b   Abrardo, Lauren A ^c   MacDougall, Conan ^d  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacteremia; Daptomycin; Vancomycin resistant enterococci; VRE

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; LINEZOLID;

ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; BLOOD CULTURE; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FEVER; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MEDICAL RECORD REVIEW; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SIDE EFFECT; TERTIARY HEALTH CARE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CREATINE KINASE; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS; FEMALE; FEVER; HOSPITALS, UNIVERSITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE; YOUNG ADULT;

EID: 67650815260     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.7.792     Document Type: Article

References (30)

1. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686-707
2. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163-170 (Pubitemid 46856806)
3. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062-1066
4. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005;52:181-186 (Pubitemid 41133543)
5. Pfizer Pharmaceuticals. Zyvox (linezolid) product information. New York, NY; 2008
6. Monarch Pharmaceuticals. Synercid IV (quinupristin/dalfopristin) product information. Bristol, TN; 2003
7. Aksoy DY, Unal S. New antimicrobial agents for the treatment of gram-positive bacterial infections. Clin Microbiol Infect 2008;14:411-420
8. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41:S303-14 (Pubitemid 41170378)
9. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004;24:41-57
10. Figueroa DA, Mangini E, Amodio-Groton M, et al. Clinical safety with daptomycin at doses greater than 6 mg/kg [abstract]. In: Program and abstracts of the 47th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2007:A-792
11. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245-3249 (Pubitemid 44527494)
12. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26:347-352 (Pubitemid 43334674)
13. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-665
14. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the morepotent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008;46:30-36 (Pubitemid 351263556)
15. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-332 (Pubitemid 351763841)
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829
17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47: 1245-1251
18. Cubist Pharmaceuticals. Cubicin (daptomycin) product information. Lexington, MA; 2007
19. Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005) [online exclusive article]. BMC Infect Dis 2007;7:29. Available from http://www. biomedcentral.com/1471-2334/7/29
20. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000;30:466-472
21. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-1239 (Pubitemid 26423158)
22. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47:1598-1603 (Pubitemid 36548543)
23. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007;54:567-571
24. Brielmaier BD, Reichley RM, Casabar E, et al. Daptomycin for treatment of vancomycin-resistant Enterococcus bloodstream infections [abstract 114]. Presented in part at the annual meeting of the American College of Clinical Pharmacy, Denver, CO, October 14-27, 2007
25. Alam M, Jimenez V. Daptomycin for the treatment of persistent vancomycin-resistant Enterococcus bacteremia and/or infective endocarditis that failed to respond to current therapeutics [abstract 1429]. Presented at the 45th annual meeting of the Infectious Diseases Society of America, San Deigo, CA, October 4-7, 2007
26. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycinresistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34:922-929 (Pubitemid 34229760)
27. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/ dalfopristin. Clin Infect Dis 2001;33:1816-1823
28. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/ dalfopristin for the treatment of infections caused by vancomycin- resistant Enterococcus faecium: Synercid emergency-use study group. J Antimicrob Chemother 1999;44:251-261 (Pubitemid 29389289)
29. Linden PK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med 2007;28: 632-645
30. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrugresistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003;36:159-168 (Pubitemid 36143412)